Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS.
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response
Imatinib treatment reduces inflammatory marker in CML patients in small study
A prospective observational cohort of 40 chronic-phase CML patients in India found imatinib significantly reduced serum TNF-α levels from 25…
Dropping inflammation markers in CML patients on imatinib treatment may help doctors predict who will respond well to the drug.
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks
Could a new leukemia drug work better and cause fewer side effects than current treatments?
In the ASC4FIRST trial, asciminib demonstrated superior efficacy vs investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP.
A new leukemia drug helped more patients reach deep disease control with fewer side effects than current standard treatments after two years…
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.
Research across Leukemia
Related studies from across the Leukemia family.
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients
Leukemia patients face eye risks that doctors must spot early now
This systematic review and meta-analysis of 1016 patients with leukemia found a 42% prevalence of overall ocular manifestations.
New data shows almost half of leukemia patients have eye issues, so regular eye checks are essential for better care
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL
Fluoroquinolone antibiotics lower febrile neutropenia risk in children with acute lymphoblastic leukemia during treatment start
This systematic review and meta-analysis of 991 children with acute lymphoblastic leukemia found that fluoroquinolone prophylaxis reduced fe…
A review of children with acute lymphoblastic leukemia shows fluoroquinolone antibiotics reduce febrile neutropenia risk. This finding sugge…
Lyophilized pegaspargase shows similar activity to liquid form in pediatric ALL
Lyophilized pegaspargase shows similar activity and safety to liquid form for pediatric leukemia patients
This phase 2 study in 89 pediatric ALL patients in Russia found that lyophilized pegaspargase had similar maximum plasma asparaginase activi…
A new form of pegaspargase works just like the liquid version for treating acute lymphoblastic leukemia in children in Russia.
Meta-analysis links maternal infection in pregnancy to childhood ALL risk
Maternal Infections During Pregnancy Linked to Higher Risk of Childhood Leukemia
This systematic review and meta-analysis of 26 studies found a modest association between maternal infection during pregnancy and childhood …
A large review of 26 studies found that maternal infections during pregnancy are associated with an increased risk of acute lymphoblastic le…
Meta-analysis links perinatal factors to childhood acute leukemia risk
Perinatal factors linked to higher leukemia risk in children
This systematic review and meta-analysis of 85 studies examined perinatal factors and childhood acute leukemia risk.
A large analysis of 85 studies finds links between birth weight, maternal history, and cesarean sections with childhood leukemia risk.
Questions about Acute Myeloid Leukemia
Can ponatinib help if my chronic myeloid leukemia is resistant to other drugs?
Yes, ponatinib can help if your CML is resistant to other drugs, especially if you have the T315I mutation, but it has serious side effects like heart problems.
Full answer →Does taking imatinib lower inflammation markers like TNF-alpha in chronic myeloid leukemia?
Yes, imatinib significantly lowers TNF-alpha levels in CML patients, and persistent high levels are linked to poor treatment response.
Full answer →Is there a new drug approved for adults with newly diagnosed chronic myeloid leukemia?
Yes, asciminib (Scemblix) was approved in 2024 for newly diagnosed Ph+ CML-CP, and nilotinib (Danziten) was also approved for this indication.
Full answer →Do specific gene changes affect how much imatinib stays in my blood?
Yes, specific gene changes in ABCB1 and ABCG2 can affect how much imatinib stays in your blood, leading to higher drug levels.
Full answer →Does a case report show myeloid sarcoma relapse appearing in the breast for Acute Myeloid Leukemia?
Yes, a case report describes a 68-year-old woman with myeloid sarcoma relapse in the breast 6 years after initial nasal cavity presentation.
Full answer →How common are gram-negative bloodstream infections in children with Acute Myeloid Leukemia?
Gram-negative bloodstream infections occur in about 27% of children with AML during induction chemotherapy, with high rates of multidrug resistance and significant mortality.
Full answer →Are there new genetic risks identified for Acute Myeloid Leukemia in specific gene locations?
Yes, a large meta-analysis identified new genetic risk loci for AML at 2p23.3, 1q23.3, 2q33.3, and 2p21, and confirmed known mutations in FLT3, NPM1, TP53, and other genes.
Full answer →What is the overall response rate for CPX-351 in therapy-related Acute Myeloid Leukemia?
The overall response rate for CPX-351 in therapy-related AML is approximately 47-61%, with complete response rates around 47-58%.
Full answer →